pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. He said: “These big pharma companies have every type of technology available to them.

Gene Silencing 100

Gene Silencing Gene RNA Genome 100

pharmaphorum

JANUARY 6, 2021

A host of other pharma companies including Gilead, Novo Nordisk, Merck & Co are also developing potential NASH drugs. Only this morning, Novo Nordisk selected the first candidate from a project with Dicerna to find new gene-silencing drugs to treat liver-related diseases including NASH.

Gene Silencing 52

Gene Silencing Regulation Pharma Companies Doctors 52

Delveinsight

AUGUST 6, 2020

Hereditary ATTR amyloidosis , also known as Familial ATTR, is an autosomal dominant disease and a result of mutations in the TTR gene, thus it is passed down from one generation to the next one. Gene-silencing Therapies. ATTR amyloidosis can be either hereditary or acquired (non-hereditary). hATTR market : In The Pipeline.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.

Marketing 94

Marketing Gene Silencing Gene Drugs 94